Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion set December 31, 2024, as the record date to determine shareholders eligible to receive year-end dividends for FY2024. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Eligible Shareholder Status via Record Date Determination This disclosure serves as…

Read More “[Disclosure] Celltrion (068270) – Decision on Closure of Shareholders’ Register (Record Date) for Cash/In-Kind Dividend / 2024-12-13” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion decided to distribute a year-end cash dividend of KRW 750 per common share (totaling KRW 153,773,154,750) with a record date of December 31, 2024. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Shareholder Meeting Approval and Cash…

Read More “[Disclosure] Celltrion (068270) – Decision on Cash Dividend / 2024-12-13” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion decided to distribute a stock dividend of 0.05 common shares per common share (totaling 10,251,543 shares) with a record date of December 31, 2024. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Shareholder Meeting Approval and Dividend…

Read More “[Disclosure] Celltrion (068270) – Decision on Stock Dividend / 2024-12-13” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion received Phase 3 Clinical Trial Application (CTA) (Part 1 & Part 2) approval from the European Medicines Agency (EMA) for CT-P51, a biosimilar candidate referencing Keytruda, targeting patients with metastatic non-squamous non-small cell lung cancer. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment…

Read More “[Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Plan for CT-P51 (Keytruda Biosimilar) in Europe (Part 1 & 2) / 2024-12-13” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen has set December 31, 2024, as the record date and established a shareholder register closure period from January 1 to January 15, 2025, to determine entitled shareholders for its 17th Annual General Shareholders Meeting. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key…

Read More “[Disclosure] ALTEOGEN (196170) – Closure of Shareholder Register or Setting of Record Date / 2024-12-12” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion decided to retire 3,011,910 previously acquired treasury common shares (valued at approx. KRW 491.8 billion) on January 6, 2025, to stabilize its stock price and enhance shareholder value. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Share…

Read More “[Disclosure] Celltrion (068270) – Decision on Retirement of Shares / 2024-12-04” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion submitted an application for a Phase 3 Clinical Trial Plan to the US FDA for CT-P44, a biosimilar referencing Darzalex, targeting patients with refractory or relapsed multiple myeloma. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring US FDA…

Read More “[Disclosure] Celltrion (068270) – Submission of Application for Phase 3 Clinical Trial Plan for CT-P44 (Darzalex Biosimilar) in the US / 2024-12-02” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Following the cancellation of the subsidiary merger, Alteogen issued this corrective filing to formally cancel its previously announced merger decision between Altos Biologics and Alteogen Healthcare. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Corrected Merger Decision Filings…

Read More “[Disclosure] ALTEOGEN (196170) – (Correction) Revocation of Merger Decision / 2024-11-29” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Following the cancellation of the subsidiary merger, Alteogen issued this corrective filing to formally cancel its previously announced share acquisition decision (859,018 shares of Altos Biologics valued at KRW 31.17B). 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of…

Read More “[Disclosure] ALTEOGEN (196170) – (Correction) Decision on Acquisition of Shares and Investment Certificates of Other Corporations / 2024-11-29” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Due to a calculation error in the merger ratio, the shareholder meeting discarded the merger proposal between Alteogen’s subsidiaries (Altos Biologics and Alteogen Healthcare), leading to the complete revocation of the merger and associated stock acquisition decisions. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s…

Read More “[Disclosure] ALTEOGEN (196170) – Revocation of Merger Decision / 2024-11-29” »